Imperative Care CEO and leadership

Fred Khosravi is a Silicon Valley medical device entrepreneur who has co-founded multiple companies, including EndoTex, Embolic Protection, Inc. (EPI), both acquired by Boston Scientific Corporation, Confluent Surgical, acquired by Tyco Healthcare, and MarketRx, acquired by Cognizant Corp. Additionally, he is the managing director of a medical device incubator called Incept. In addition to Confluent, EPI, and AccessClosure, Incept has spawned several other novel device companies including Sadra Medical (acquired by Boston Scientific), Ostial Corp., HotSpur, Inc., and Ocular Therapeutix, Inc., where Fred serves as co-founder and Director/Chairman. Fred also served on the boards of Kerberos before its acquisition by FoxHollow Technologies and Advanced Stent Technologies prior to its acquisition by Boston Scientific. He holds a B.S. in mechanical engineering, and graduated summa cum laude, obtaining a M.S. in mechanical engineering from Tennessee Tech University.

Daniel Davis joined Imperative Care in 2020 and brings 19 years of experience in sales, marketing, and business development with both early stage and Fortune 500 companies in medical devices and before that in software and consumer products.

Prior to joining Imperative Care, Mr. Davis was Chief Commercial Officer and President, North America for Penumbra, Inc. where he helped lead the company's IPO and successful entry into the peripheral vascular market. Daniel earned increasing responsibility in the company as he progressed from a leader in the marketing organization to Vice President of Strategy to President, North America.

He joined Penumbra in 2007 in the pre-commercial phase to launch the first FDA cleared intracranial delivery catheter (Neuron), the first FDA cleared aspiration system for neurovascular mechanical thrombectomy (Penumbra System), and the Penumbra Coil 400 for the treatment of intracranial aneurysms. Previously, he held sales and marketing positions of increasing responsibility at Boston Scientific (now Stryker Neurovascular) as well as roles at Newell Rubbermaid and Trilogy. Daniel holds an AB in History and in Economics from Duke University.

Matthew C. Garrett has served as iRhythm’s Chief Financial Officer since January 2013. Previously, he served as Chief Financial Officer of Navigenics, Inc., a provider of genetic testing for common health conditions. Prior to that, he served as Director of Business Development at Corventis Inc., a health monitor applications company and he also served as Vice President of Finance, Chief Accounting Officer and Treasurer for Cogentus Pharmaceuticals Inc., a developer of prescription pharmaceutical products. Before that, Mr. Garrett served as Finance Director in Research & Development and Director of Strategic Marketing and Pricing at Affymetrix, Inc. Earlier in his career, he held various finance roles at Guidant Corporation, a medical technology company focused on cardiac and vascular solutions. Mr. Garrett has a B.A. in Finance from the University of Iowa, Iowa City and an M.B.A. from the Kelley School of Business, Indiana University Bloomington.

Yi is a seasoned medtech executive/entrepreneur with over 22 years of experience in the medical device industry. Yi is the Chief Technology Officer of Incept LLC, a highly successful medical device accelerator located in Silicon Valley and Boston. Prior to Imperative Care, he was the COO of Ostial Corporation, overseeing development, production, and commercialization. Previously he was the co-founder and VP of R&D at CAVU, a medical device startup developing novel technologies for the treatment of obesity. Yi held senior management roles at Boston Scientific Corporation (BSX) and EndoTex Interventional Systems, Inc. (acquired by BSX). Other positions Yi held were technical project manager at EP Technologies, Inc. (acquired by BSX), and technical leader at Guided Medical Systems, Inc. Yi is the inventor or co-inventor on multiple patent applications. He holds a B.S. in Mechanical Engineering from UC Berkeley and an M.S. in Mechanical Engineering from Stanford University.

Fred Khosravi is a Silicon Valley medical device entrepreneur who has co-founded multiple companies, including EndoTex, Embolic Protection, Inc. (EPI), both acquired by Boston Scientific Corporation, Confluent Surgical, acquired by Tyco Healthcare, and MarketRx, acquired by Cognizant Corp. Additionally, he is the managing director of a medical device incubator called Incept. In addition to Confluent, EPI, and AccessClosure, Incept has spawned several other novel device companies including Sadra Medical (acquired by Boston Scientific), Ostial Corp., HotSpur, Inc., and Ocular Therapeutix, Inc., where Fred serves as co-founder and Director/Chairman. Fred also served on the boards of Kerberos before its acquisition by FoxHollow Technologies and Advanced Stent Technologies prior to its acquisition by Boston Scientific. He holds a B.S. in mechanical engineering, and graduated summa cum laude, obtaining a M.S. in mechanical engineering from Tennessee Tech University.

Daniel Davis joined Imperative Care in 2020 and brings 19 years of experience in sales, marketing, and business development with both early stage and Fortune 500 companies in medical devices and before that in software and consumer products.

Prior to joining Imperative Care, Mr. Davis was Chief Commercial Officer and President, North America for Penumbra, Inc. where he helped lead the company's IPO and successful entry into the peripheral vascular market. Daniel earned increasing responsibility in the company as he progressed from a leader in the marketing organization to Vice President of Strategy to President, North America.

He joined Penumbra in 2007 in the pre-commercial phase to launch the first FDA cleared intracranial delivery catheter (Neuron), the first FDA cleared aspiration system for neurovascular mechanical thrombectomy (Penumbra System), and the Penumbra Coil 400 for the treatment of intracranial aneurysms. Previously, he held sales and marketing positions of increasing responsibility at Boston Scientific (now Stryker Neurovascular) as well as roles at Newell Rubbermaid and Trilogy. Daniel holds an AB in History and in Economics from Duke University.